Cargando…
Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy
BACKGROUND: To evaluate the efficacy and safety of recombinant human serum albumin /granulocyte colony-stimulating factor (rHSA/G-CSF) in breast cancer following receipt of cytotoxic agents. METHODS: The phase 1b trial assessed the pharmacokinetics, pharmacodynamics, and safety of dose-escalation, r...
Autores principales: | Chen, Shanshan, Han, Yiqun, Ouyang, Quchang, Lu, Jianguo, Zhang, Qingyuan, Yang, Shun’e, Wang, Jingfen, Huang, Haixin, Liu, Hong, Shao, Zhimin, Li, Hui, Chen, Zhendong, Sun, Sanyuan, Geng, Cuizhi, Lu, Junguo, Sun, Jianwei, Wang, Jiayu, Xu, Binghe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010964/ https://www.ncbi.nlm.nih.gov/pubmed/33789616 http://dx.doi.org/10.1186/s12885-021-08093-z |
Ejemplares similares
-
A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer
por: Wang, Jiayu, et al.
Publicado: (2023) -
Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2023) -
Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation‐wide multicenter study
por: Guo, Fengzhu, et al.
Publicado: (2021) -
Granulocyte colony-stimulating factor (G-CSF) mediates bone resorption in periodontitis
por: Yu, Hui, et al.
Publicado: (2021) -
Granulocyte colony-stimulating factor and leukemogenesis.
por: de Figueiredo, Lorena Lobo, et al.
Publicado: (2004)